Laughing Water Capital on X
GSK reportedly made three bids for AnaptysBio over the past year, making the trial outcome a potential determinant of sale price rather than a barrier to a deal.
NASDAQ
Anaptysbio, INC
ANAB
8 articles
$1.7B Market cap · 2026-08-24
Laughing Water Capital on X
@FriendlyCapMgmt @thecontracap there have been some things i view as negative for $ANAB and some that are positive. but in my view in order to make this investment you have to focus on the future cashflows, not the trial.
Laughing Water Capital on X
ANAB could sell its royalty stream if it loses, preserving future cash flows despite a stock decline. The board added RPRX’s former CFO four months earlier.
Laughing Water Capital on X
GSK and AnaptysBio face a collaboration-contract dispute after the GSK manager overseeing the $ANAB partnership said GSK violated the agreement.
Laughing Water Capital on X
AnaptysBio’s contract-law position against GSK could preserve Delaware’s longstanding approach to contractual disputes.
Laughing Water Capital on X
GSK’s position in the ANAB dispute could let acquirers disavow a purchased subsidiary’s obligations, a result characterized as catastrophic for Delaware contract law.
Laughing Water Capital on X
GSK faces a July 14 trial over Jemperli, with AnaptysBio claiming rights that could restrict PD-1 partnerships. The dispute could end in a settlement or acquisition.
AnaptysBio (ANAB)
AnaptysBio’s Jemperli royalty receipts rise after a Sagard financing obligation ends in 2027.
Investor Letters
Letters that discuss ANAB.
